Structure via PubChem · Public domain (PubChem)
talsaclidine
Sign in to saveTalsaclidine (WAL-2014) is a non-selective muscarinic acetylcholine receptor agonist which acts as a full agonist at the M1 subtype, and as a partial agonist at the M2 and M3 subtypes. It was under development for the treatment of Alzheimer's disease but showed only modest or poor efficacy in rhesus monkeys and humans, respectively, perhaps due to an array of dose-limiting side effects including increased heart rate and blood pressure, increased salivation, urinary frequency and burning upon urination, increased lacrimation and nasal secretion, abnormal accommodation, heartburn, upset stomach
In the Vinony graph
Within Vinony's link graph, talsaclidine is referenced by 400 other articles, and connects out to atropine, agonist and muscarinic acetylcholine receptor family.
It is catalogued under topics including Abandoned drugs, Chemical pages without DrugBank identifier and Drugs not assigned an ATC code.
Its subject is documented across 5 Wikipedia language editions.
Chemical data
- Formula
- C10H15NO
- Molecular weight
- 165.23 g/mol
- IUPAC name
- (3R)-3-prop-2-ynoxy-1-azabicyclo[2.2.2]octane
- SMILES
- C#CCO[C@H]1CN2CCC1CC2
- InChIKey
- XVFJONKUSLSKSW-JTQLQIEISA-N
- XLogP
- 0.8
- Polar surface area
- 12.5 Ų
- H-bond donors
- 0
- H-bond acceptors
- 2
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Phase 2
- Molecule type
- Small molecule
- Indications
- Alzheimer disease
via ChEMBL · EBI
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 165.115
Show 4 more facts
- canonical SMILES
- C#CCOC1CN2CCC1CC2
- chemical formula
- C₁₀H₁₅NO
- isomeric SMILES
- C#CCO[C@H]1CN2CCC1CC2
- Commons category
- Talsaclidine
Sources (2)
via Wikidata · CC0
~1 min read
Encyclopedic overview
2 sectionsContents
- See also
- References
Talsaclidine (WAL-2014) is a non-selective muscarinic acetylcholine receptor agonist which acts as a full agonist at the M1 subtype, and as a partial agonist at the M2 and M3 subtypes. It was under development for the treatment of Alzheimer's disease but showed only modest or poor efficacy in rhesus monkeys and humans, respectively, perhaps due to an array of dose-limiting side effects including increased heart rate and blood pressure, increased salivation, urinary frequency and burning upon urination, increased lacrimation and nasal secretion, abnormal accommodation, heartburn, upset stomach as well as cramps, nausea, vomiting and diarrhea, excessive sweating and palpitations.
== See also == Aceclidine Vedaclidine
Excerpted from Wikipedia’s “talsaclidine” article, available under the CC BY-SA 4.0 licence.